Tag:
FluLaval Quadrivalent
Latest Headlines
Latest Headlines
Fluviral, FluLaval Tetra production on hold at Glaxo's troubled Quebec plant
GlaxoSmithKline is in the process of reviewing regulatory results from a June inspection that found that 10 areas of its Ste. Foy, Quebec, vaccine manufacturing plant needed improvements. But in the meantime, Health Canada has imposed a condition on the facility's license, requiring notice before Glaxo resumes production of Fluviral and FluLaval Tetra.
Canada gives GSK 30-day deadline for turnaround plans at FluLaval plant
Last month, the FDA chided GlaxoSmithKline over issues at its Canadian flu vaccine plant, home to production of seasonal product FluLaval. Now, it's got another regulator on its case, too: Health Canada wants to see GlaxoSmithKline lay out plans for correcting problems at the facility, and it's giving the company 30 days to do it.
FDA slaps Glaxo with warning letter for FluLaval plant
After an inspection from March 31 to April 9 of this year, the FDA didn't much like what it saw at GlaxoSmithKline's Ste-Foy plant in Quebec, home of the company's FluLaval influenza vaccines. Now, the agency has issued a warning, pointing its finger at the British drugmaker for not doing its part to avoid contamination.
Improved vaccines mean flu immunization can start earlier
Whereas in the past, a vaccine given in August would offer little protection come February, new formulations are extending the period of immunity. Healthcare professionals have responded by adjusting the advice they give to their patients.
